Clinical Trial Update: Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer [NA]

View source ↗

Summary

The clinical trial evaluating losartan for pulmonary fibrosis in patients with stage I–III non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pulmonary Fibrosis
• Radiation-induced Pulmonary Fibrosis

Drugs mentioned

• Losartan (losartan)

Snippet

Sponsor: University of South Florida | Conditions: Dyspnea, Lung Cancer | NA | Status: WITHDRAWN